Formosa Pharmaceuticals (TPE:6838) signed an exclusive licensing deal with Cipla to commercialize a drug for post-operative inflammation and pain.
The drug, dubbed APP13007, will be commercialized in 11 countries, including India, Malaysia, and South Africa, according to a Tuesday Taiwan Exchange filing.
The deal includes upfront, milestone, and royalty payments, though financial terms remain confidential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.